Histone deacetylase inhibitors in hematological malignancies and solid tumors (Q38344675)

2 September 2017

1 reference

title

Histone deacetylase inhibitors in hematological malignancies and solid tumors (English)

1 reference

2 September 2017

Pusoon Chun

1

1 reference

PubMed ID

25653088

2 September 2017

language of work or name

1 reference

5 February 2015

1 reference

Archives of Pharmacal Research

2 September 2017

1 reference

2 September 2017

38

1 reference

2 September 2017

6

1 reference

2 September 2017

933-949

1 reference

https://scigraph.springernature.com/pub.10.1007/s12272-015-0571-1

2 September 2017

0 references

cites work

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Antineoplastic chemotherapy induced QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Inside HDAC with HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors specifically kill nonproliferating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Apoptosis in cancer: key molecular signaling pathways and therapy targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Duration of nuclear NF-kappaB action regulated by reversible acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Compromised Structure and Function of HDAC8 Mutants Identified in Cornelia de Lange Syndrome Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

HDAC11 is a novel drug target in carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

SHP represses transcriptional activity via recruitment of histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone acetylation in chromatin structure and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

p15INK4b in HDAC inhibitor‐induced growth arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Identification of novel isoform-selective inhibitors within class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone acetylases and deacetylases in cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Deacetylation of p53 modulates its effect on cell growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

MyoD is functionally linked to the silencing of a muscle-specific regulatory gene prior to skeletal myogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Regulation of E2F1 activity by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Macrocyclic histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone acetylation reduces nucleosome core particle linking number change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase 8 in neuroblastoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase 3 associates with and represses the transcription factor GATA-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

The role of histone deacetylases (HDACs) in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors: insights into mechanisms of lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Increased expression of histone deacetylase 2 is found in human gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Prolonged QTc interval and risk of sudden cardiac death in a population of older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Molecularly targeted oncology therapeutics and prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Class II histone deacetylases: versatile regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Sumoylation and acetylation play opposite roles in the transactivation of PLAG1 and PLAGL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

The emerging role of class II histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0571-1

10.1007/S12272-015-0571-1

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

25653088

Dimensions Publication ID

2 September 2017

0 references

1 reference

PubMed ID

25653088